Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer

In brief

The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.

Key facts

Study ID

NCT01289353

Run by

NYU Langone Health

People needed

92

Starts

2009-03-06

Expected to finish

2019-07-08

Last updated by the study team

2021-01-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age older than 18
• Pre- or post-menopausal women with Stage I and II breast cancer, triple negative tumors
• Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
• Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (Tumors < 5 mm in size do not require nodal assessment) or after mastectomy
• No previous chemotherapy
• Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document

You may not qualify if…

• Previous radiation therapy to the ipsilateral breast
• Active connective tissue disorders, such as lupus or scleroderma
• Pregnant or lactating women

Where it is running

• NYU Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.